Our Clinical Trials

Clinical Trials for CLR 131

We are currently enrolling patients for a Waldenstrom’s macroglobulinemia (WM) Pivotal Trial utilizing CLR 131. Additionally, CLR 131 is being evaluated in a multi cohort CLOVER-1 Phase 2 study in adult B-cell malignancies and the CLOVER-2 Phase 1 study for a variety of pediatric cancers.

Clinical Trials Overview

Clinical trials are a fundamental necessity in the development and advancement of new treatment options for battling cancer, and you may not know it, but you could play an important role. Clinical trials need patients to enroll in them so that they can advance through the processes necessary to potentially get a new treatment to market. Your participation in clinical trials can help create a better treatment landscape for future cancer patients.

To learn more general information about clinical trials, please visit www.cancer.org and find the Clinical Studies section.

Part A of this study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of CLR 131 in patients with WM that failed Bruton's tyrosine kinase inhibitors (BTKi).

Status

Recruiting

Relapsed or Refractory Select B-Cell Malignancies Clinical Trial: View Clinical Trial

The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.

Status

Recruiting

Children With Relapsed or Refractory Malignant Cancer Clinical Trial: View Clinical Trial

The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.

Status

Active, not recruiting

Relapsed or Refractory Multiple Myeloma Clinical Trial: View Clinical Trial

Enrollment

For more information on enrollment into our current clinical trials, please contact us or visit clinicaltrials.gov for location information.

Contact Us Visit ClinicalTrials.gov

Expanded Access Policy

Learn More